MLLCF
Price
$3.50
Change
-$0.00 (-0.00%)
Updated
Jan 12 closing price
Capitalization
152.2M
Intraday BUY SELL Signals
URGN
Price
$18.91
Change
-$0.62 (-3.17%)
Updated
Jan 16, 11:59 AM (EDT)
Capitalization
914.65M
55 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

MLLCF vs URGN

Header iconMLLCF vs URGN Comparison
Open Charts MLLCF vs URGNBanner chart's image
Molecular Partners AG
Price$3.50
Change-$0.00 (-0.00%)
Volume$500
Capitalization152.2M
UroGen Pharma
Price$18.91
Change-$0.62 (-3.17%)
Volume$248
Capitalization914.65M
MLLCF vs URGN Comparison Chart in %
MLLCF
Daily Signal:
Gain/Loss:
URGN
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
MLLCF vs. URGN commentary
Jan 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MLLCF is a Hold and URGN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 16, 2026
Stock price -- (MLLCF: $3.50 vs. URGN: $19.54)
Brand notoriety: MLLCF and URGN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MLLCF: 29% vs. URGN: 117%
Market capitalization -- MLLCF: $152.2M vs. URGN: $914.65M
MLLCF [@Biotechnology] is valued at $152.2M. URGN’s [@Biotechnology] market capitalization is $914.65M. The market cap for tickers in the [@Biotechnology] industry ranges from $111.36B to $0. The average market capitalization across the [@Biotechnology] industry is $2.26B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MLLCF’s FA Score shows that 0 FA rating(s) are green whileURGN’s FA Score has 0 green FA rating(s).

  • MLLCF’s FA Score: 0 green, 5 red.
  • URGN’s FA Score: 0 green, 5 red.
According to our system of comparison, URGN is a better buy in the long-term than MLLCF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MLLCF’s TA Score shows that 3 TA indicator(s) are bullish while URGN’s TA Score has 4 bullish TA indicator(s).

  • MLLCF’s TA Score: 3 bullish, 4 bearish.
  • URGN’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both MLLCF and URGN are a bad buy in the short-term.

Price Growth

MLLCF (@Biotechnology) experienced а 0.00% price change this week, while URGN (@Biotechnology) price change was -16.74% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.72%. For the same industry, the average monthly price growth was +2.38%, and the average quarterly price growth was +41.99%.

Reported Earning Dates

URGN is expected to report earnings on Mar 12, 2026.

Industries' Descriptions

@Biotechnology (+0.72% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
URGN($915M) has a higher market cap than MLLCF($152M). MLLCF YTD gains are higher at: 0.000 vs. URGN (-16.567). MLLCF has higher annual earnings (EBITDA): -58.01M vs. URGN (-144.14M). URGN has more cash in the bank: 127M vs. MLLCF (105M). MLLCF has less debt than URGN: MLLCF (1.53M) vs URGN (128M). URGN has higher revenues than MLLCF: URGN (96.5M) vs MLLCF (0).
MLLCFURGNMLLCF / URGN
Capitalization152M915M17%
EBITDA-58.01M-144.14M40%
Gain YTD0.000-16.567-
P/E RatioN/AN/A-
Revenue096.5M-
Total Cash105M127M83%
Total Debt1.53M128M1%
FUNDAMENTALS RATINGS
MLLCF vs URGN: Fundamental Ratings
MLLCF
URGN
OUTLOOK RATING
1..100
3774
VALUATION
overvalued / fair valued / undervalued
1..100
46
Fair valued
59
Fair valued
PROFIT vs RISK RATING
1..100
10097
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
8047
P/E GROWTH RATING
1..100
85100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MLLCF's Valuation (46) in the null industry is in the same range as URGN (59) in the Biotechnology industry. This means that MLLCF’s stock grew similarly to URGN’s over the last 12 months.

URGN's Profit vs Risk Rating (97) in the Biotechnology industry is in the same range as MLLCF (100) in the null industry. This means that URGN’s stock grew similarly to MLLCF’s over the last 12 months.

MLLCF's SMR Rating (97) in the null industry is in the same range as URGN (100) in the Biotechnology industry. This means that MLLCF’s stock grew similarly to URGN’s over the last 12 months.

URGN's Price Growth Rating (47) in the Biotechnology industry is somewhat better than the same rating for MLLCF (80) in the null industry. This means that URGN’s stock grew somewhat faster than MLLCF’s over the last 12 months.

MLLCF's P/E Growth Rating (85) in the null industry is in the same range as URGN (100) in the Biotechnology industry. This means that MLLCF’s stock grew similarly to URGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MLLCFURGN
RSI
ODDS (%)
Bullish Trend 1 day ago
52%
Bullish Trend 1 day ago
80%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
51%
Bullish Trend 1 day ago
82%
Momentum
ODDS (%)
Bullish Trend 1 day ago
53%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
61%
N/A
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
41%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
59%
Bearish Trend 1 day ago
87%
Advances
ODDS (%)
N/A
Bullish Trend 9 days ago
82%
Declines
ODDS (%)
N/A
Bearish Trend 3 days ago
87%
BollingerBands
ODDS (%)
N/A
Bullish Trend 1 day ago
77%
Aroon
ODDS (%)
Bearish Trend 1 day ago
62%
Bearish Trend 1 day ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
MLLCF
Daily Signal:
Gain/Loss:
URGN
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYDAX116.530.69
+0.60%
Rydex Dow Jones Industrial Average® A
CRVRX8.150.04
+0.49%
NYLI CBRE Real Estate Fund Investor Cl
WLGRX32.680.07
+0.21%
Nomura Large Cap Growth R
LMOPX44.550.02
+0.04%
Patient Opportunity C
VEUAX41.41-0.18
-0.43%
JPMorgan Europe Dynamic A

MLLCF and

Correlation & Price change

A.I.dvisor indicates that over the last year, MLLCF has been loosely correlated with ENSC. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if MLLCF jumps, then ENSC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MLLCF
1D Price
Change %
MLLCF100%
N/A
ENSC - MLLCF
37%
Loosely correlated
-3.23%
CYYNF - MLLCF
31%
Poorly correlated
N/A
HNSBF - MLLCF
27%
Poorly correlated
N/A
URGN - MLLCF
26%
Poorly correlated
+4.27%
GNPX - MLLCF
24%
Poorly correlated
+14.98%
More

URGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, URGN has been loosely correlated with AIM. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if URGN jumps, then AIM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To URGN
1D Price
Change %
URGN100%
+4.27%
AIM - URGN
39%
Loosely correlated
+2.29%
CYYNF - URGN
38%
Loosely correlated
N/A
PHAT - URGN
36%
Loosely correlated
-1.06%
ACLX - URGN
33%
Loosely correlated
-2.20%
AURA - URGN
33%
Loosely correlated
-2.85%
More